Literature DB >> 20656109

PARP inhibition in BRCA-mutated breast and ovarian cancers.

Stephen L Chan1, Tony Mok.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20656109     DOI： 10.1016/S0140-6736(10)61119-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

1.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

Authors:  Paz Polak; Jaegil Kim; Lior Z Braunstein; Rosa Karlic; Nicholas J Haradhavala; Grace Tiao; Daniel Rosebrock; Dimitri Livitz; Kirsten Kübler; Kent W Mouw; Atanas Kamburov; Yosef E Maruvka; Ignaty Leshchiner; Eric S Lander; Todd R Golub; Aviad Zick; Alexandre Orthwein; Michael S Lawrence; Rajbir N Batra; Carlos Caldas; Daniel A Haber; Peter W Laird; Hui Shen; Leif W Ellisen; Alan D D'Andrea; Stephen J Chanock; William D Foulkes; Gad Getz
Journal:  Nat Genet       Date:  2017-08-21       Impact factor: 38.330

Review 2.  Harnessing synthetic lethal interactions in anticancer drug discovery.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

3.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

Authors:  Anand G Patel; Jann N Sarkaria; Scott H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

4.  Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.

Authors:  Allison N DuRoss; Megan J Neufeld; Madeleine R Landry; Justin G Rosch; Colin T Eaton; Gaurav Sahay; Charles R Thomas; Conroy Sun
Journal:  ACS Appl Mater Interfaces       Date:  2019-03-21       Impact factor: 9.229

5.  BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.

Authors:  Lisa M Maurer; Jessica D Daley; Elina Mukherjee; Rosemarie E Venier; Claire M Julian; Nathanael G Bailey; Michelle F Jacobs; Chandan Kumar-Sinha; Haley Raphael; Nivitha Periyapatna; Kurt Weiss; Katherine A Janeway; Rajen Mody; Peter C Lucas; Linda M McAllister-Lucas; Kelly M Bailey
Journal:  Cancer Res Commun       Date:  2022-04-20

6.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

7.  Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models.

Authors:  Manal Mehibel; Yu Xu; Caiyun G Li; Eui Jung Moon; Kaushik N Thakkar; Anh N Diep; Ryan K Kim; Joshua D Bloomstein; Yiren Xiao; Julien Bacal; Joshua C Saldivar; Quynh-Thu Le; Karlene A Cimprich; Erinn B Rankin; Amato J Giaccia
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

Review 8.  The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.

Authors:  Silvana B De Lorenzo; Anand G Patel; Rachel M Hurley; Scott H Kaufmann
Journal:  Front Oncol       Date:  2013-09-11       Impact factor: 6.244

Review 9.  Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.

Authors:  Stephen L Chan; Sin T Chan; Eric H Chan; Zhe-Xi He
Journal:  Chin J Cancer       Date:  2014-01-29

10.  Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.

Authors:  Yi Yu; Mingxing Zhang; Xiaoyan Zhang; Qingqing Cai; Shanshan Hong; Wei Jiang; Congjian Xu
Journal:  J Hematol Oncol       Date:  2014-05-06       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.